

REMARKS

Claims 1-31 were pending in this application. Claims 27-31 are canceled without prejudice as directed to non-elected subject matter. Applicant reserves the right to pursue all canceled subject matter in one or more continuing applications. After entry of this Amendment, **claims 1-26 are pending in this application.**

The Office contends that the pending claims are directed to two “distinct” inventions and has required restriction to one alleged invention under 35 U.S.C. §121. The two Groups provided by the Office are:

- | | |
|-----------------------|--|
| Group I (claim 27-31) | drawn to a pharmaceutical composition comprising a therapeutically effective amount of a drug combination comprising neostigmine and glycopyrrolate in a weight ratio of neostigmine to glycopyrrolate of about 2.5:1 to about 10:1; and |
| Group II (claim 1-26) | drawn to a method of bowel care, comprising chronically administering a therapeutically effective amount of a drug combination comprising an acetylcholinesterase inhibitor and an anti-cholinergic agent to a subject having a chronic intestinal pseudo-obstruction. |

For prosecution in the present application, Applicant elects the alleged invention of Group II (claims 1-26). The claims have been amended in conformance with this election.

Substantive examination of the pending claims is respectfully requested. The Examiner is invited to call the undersigned if the Examiner believes that a telephone interview would facilitate substantive examination of this application.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By: /Debra A. Gordon/
Registration No. 54,128